Drug intelligence / Profile preview

bupivacaine + sufentanil

Development stage
Phase 4
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Epidural, Intrathecal
01

Overview

Bupivacaine + sufentanil is a fixed-dose combination of two drugs used primarily for regional anesthesia and analgesia, especially in obstetric settings such as labor and cesarean delivery. Bupivacaine is an amide-type local anesthetic that works by blocking voltage-gated sodium channels on neuronal membranes, thereby inhibiting nerve impulse conduction and producing loss of sensation. Sufentanil is a potent synthetic opioid agonist at the mu-opioid receptor, providing strong analgesic effects. When combined (typically via epidural or intrathecal administration), this regimen offers superior pain relief compared to bupivacaine alone—prolonging the duration of analgesia, reducing breakthrough pain during surgery or labor, shortening sensory block onset time, and delaying the need for additional analgesics. The addition of sufentanil may increase certain side effects such as pruritus but does not significantly increase adverse maternal or fetal outcomes when used appropriately[1][2][3][4][7][9][10].

Other names
bupivacaine and sufentanilbupivacaine-sufentanil combination
02

Targets

MOR (Mu opioid receptor)PTGER1 (Prostaglandin E Receptor 1)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on bupivacaine + sufentanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupivacaine + sufentanil.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call